Login / Signup

Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors.

Satı Coşkun YazganEmre YekedüzGüngör UtkanYuksel Urun
Published in: The Prostate (2022)
In this study, we demonstrated that PIV was an independent prognostic factor for OS in patients with mCRPC treated with AA or enzalutamide. Additionally, PIV-LDH combined score may be considered a promising composite peripheral blood-based biomarker to predict OS in those patients.
Keyphrases
  • prognostic factors
  • peripheral blood
  • newly diagnosed
  • end stage renal disease
  • prostate cancer
  • ejection fraction
  • oxidative stress
  • chronic kidney disease
  • peritoneal dialysis
  • patient reported outcomes